How Does Telfast Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Telfast Works
- Active Ingredient: Fexofenadine hydrochloride – a second‑generation, non‑sedating antihistamine.
- Primary Action: Selectively blocks peripheral H1 histamine receptors, preventing allergy symptoms without crossing the blood‑brain barrier.
- Onset & Duration: Relief begins within 1 hour; a single 120 mg dose controls hay fever symptoms for 24 hours.
- Metabolism: Minimally metabolised (no CYP involvement); excreted largely unchanged in faeces (80%) and urine (11%). Half‑life ~14 hours.
- Safety: Non‑sedating; suitable for adults and children ≥12 years. Caution in severe renal impairment.
Telfast (fexofenadine) is a widely prescribed antihistamine for hay fever. It works by selectively blocking histamine receptors outside the brain, providing effective 24‑hour relief from sneezing, itchy eyes, and runny nose without causing drowsiness.
Important Medical Advice
Stop taking Telfast and seek immediate medical help if you experience swelling of the face, lips, tongue or throat, difficulty breathing, flushing, or chest tightness – these may be signs of a serious allergic reaction. Also consult your doctor before use if you have kidney or liver problems, heart disease, or are elderly.
Chemical Composition & Molecular Structure
Telfast 120 mg film‑coated tablets contain fexofenadine hydrochloride, a zwitterionic second‑generation antihistamine. Each tablet provides 120 mg of fexofenadine hydrochloride, equivalent to 112 mg fexofenadine base.
Structural Details
(±)‑4‑[1‑hydroxy‑4‑[4‑(hydroxydiphenylmethyl)‑1‑piperidinyl]butyl]‑α,α‑dimethylbenzeneacetic acid hydrochloride
A piperidine derivative, it is the active carboxylic acid metabolite of terfenadine. The molecule exists as a zwitterion at physiological pH, which limits its ability to cross the blood‑brain barrier and contributes to its non‑sedating profile.
Key Pharmaceutical Properties
| Property | Value |
|---|---|
| Molecular formula | C₃₂H₃₉NO₄ · HCl |
| Molecular weight | 538.1 g/mol |
| LogP (octanol/water) at pH 7.4 | 3.2 |
| pKa | 7.1 (zwitterion) |
| Protein binding | 60–70% (primarily to albumin and α₁‑acid glycoprotein) |
🗒️ Pharmaceutical insight: The tablet core contains croscarmellose sodium as a disintegrant, and the film coating includes iron oxides (E172) which give the tablet its peach colour. Excipients are carefully chosen to ensure consistent release and absorption.
Mechanism of Action: Antihistamine Pathway
Fexofenadine is a potent, selective, and peripherally acting H1 receptor antagonist. It does not prevent histamine release but competitively blocks its binding at the receptor site.
- Histamine challenge: In allergic conditions, allergens trigger mast cell degranulation, releasing histamine. Histamine then binds to H1 receptors on nerve endings, smooth muscle, and glandular cells, producing sneezing, itching, rhinorrhoea, and conjunctival irritation.
- Receptor blockade: Fexofenadine binds preferentially to the H1 receptor with high affinity, preventing histamine from exerting its effects. It exhibits negligible affinity for other receptor types (muscarinic, α‑adrenergic, dopamine, serotonin).
- Peripheral selectivity: Due to its zwitterionic structure and P‑glycoprotein efflux at the blood‑brain barrier, fexofenadine penetration into the CNS is minimal, thereby avoiding sedation – a key advantage over first‑generation antihistamines.
| Feature | Fexofenadine | First‑generation (e.g., chlorphenamine) |
|---|---|---|
| CNS penetration | Very low (non‑sedating) | High (sedating) |
| H1 receptor selectivity | High | Moderate (cross‑reactivity) |
| Onset of action | 1 hour | 30‑60 minutes |
| Duration | 24 hours | 4‑6 hours |
🗒️ Physiological insight: By blocking H1 receptors on sensory nerves, fexofenadine reduces the sneeze reflex and nasal itching; on endothelial cells, it decreases vascular permeability and thus reduces rhinorrhoea and watery eyes.
Absorption & Distribution (Pharmacokinetics)
Following oral administration, fexofenadine is rapidly absorbed. The absolute bioavailability is approximately 30%, largely because of intestinal first‑pass efflux by P‑glycoprotein.
Absorption
Peak plasma concentrations are reached 1–3 hours after dosing. Food may slightly delay absorption but does not affect the extent. Concomitant administration with aluminium/magnesium‑containing antacids reduces absorption; a 2‑hour interval is recommended.
Distribution
Fexofenadine is 60‑70% bound to plasma proteins. The volume of distribution is 5.4‑5.8 L/kg, indicating extensive tissue distribution, but it remains peripheral and does not accumulate in the CNS.
In patients with mild to moderate renal impairment, peak plasma levels increase by about 50‑100%; therefore a lower starting dose may be considered. Hepatic impairment does not significantly alter pharmacokinetics.
Metabolic Effects & Elimination
Metabolism: Fexofenadine undergoes minimal metabolism. Only about 5% of a dose is metabolised, primarily by the gut microflora; it is not a substrate for cytochrome P450 enzymes. This means it has very low potential for drug‑drug interactions via CYP inhibition or induction.
Elimination: The drug is eliminated largely unchanged. Following oral administration, approximately 80% of the dose is recovered in faeces (as unchanged fexofenadine) and 11% in urine. The terminal elimination half‑life is around 14 hours after multiple doses, supporting once‑daily dosing.
⚠️ Renal caution: In patients with severe renal impairment (creatinine clearance ≤40 mL/min), peak plasma levels are higher and half‑life prolonged. A starting dose of 30 mg once daily is recommended in such cases.
Clinical Efficacy in Allergic Rhinitis (Hay Fever)
Telfast 120 mg is indicated for the relief of symptoms associated with seasonal allergic rhinitis. In clinical trials, fexofenadine significantly reduced total symptom scores (sneezing, rhinorrhoea, itchy nose/palate, and itchy/watery/red eyes) compared with placebo.
- Onset: Symptom relief begins within 60 minutes of administration.
- Duration: A single dose provides 24‑hour control, making it suitable for once‑daily use.
- Non‑sedating profile: Objective tests (e.g., driving simulation, cognitive function) confirm no significant difference from placebo, allowing patients to carry out normal daily activities.
- Quality of life: Improvements in sleep, daily activities, and overall well‑being have been demonstrated in rhinoconjunctivitis‑specific quality‑of‑life questionnaires.
For adolescents (12 years and older) and adults, the recommended dose is one 120 mg tablet daily. The safety and efficacy in children under 12 have not been established for this strength.
Telfast FAQs
How long does Telfast take to start working?
Telfast begins to relieve hay fever symptoms within 1 hour of taking the tablet. Maximum effect is usually seen within 2‑3 hours and lasts for 24 hours.
Can I take Telfast every day?
Yes, Telfast 120 mg is designed for once‑daily use throughout the hay fever season. Always follow the dosage prescribed by your doctor or pharmacist.
Does Telfast cause drowsiness?
Telfast is a non‑sedating antihistamine. Clinical studies show it does not cause significant drowsiness, but a small number of people may still experience sleepiness. Always assess your own response before driving.
Can I drink alcohol while taking Telfast?
There is no known interaction with alcohol, but it is wise to limit alcohol intake as it may worsen potential side effects like dizziness or drowsiness in sensitive individuals.
Is Telfast safe for children?
Telfast 120 mg is approved for adolescents aged 12 years and older. For younger children, lower‑strength formulations or other antihistamines may be more suitable; consult your GP or pharmacist.
Need Telfast for Hay Fever?
If you suffer from seasonal allergies and think Telfast may help, speak to a UK‑registered pharmacist or doctor online. A quick consultation can confirm if it's right for you.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Allergy ConsultationRelated Telfast Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co‑founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up‑to‑date.
Medical Doctor
Dr. Feroz is a GMC‑registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co‑founder and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 12 March 2026
Next Review: 12 September 2026
Published on: 12 March 2026
Last Updated: 12 March 2026